ObesityPhase 2NCT07215559
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
A Phase 2 study testing Macupatide and Eloralintide in people with Obesity and Overweight, run by Eli Lilly and Company at 42 sites in 4 countries.
Trial summary
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Obesity, Overweight, Diabetes Mellitus, Type 2
- What is being tested?
- Macupatide and Eloralintide
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 42 sitesin 4 countries
- Study dates
- 16 Oct 2025to May 2027
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have type 2 diabetes
- Have an HbA1c ≥7.5% to ≤10.5% at screening
- Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
- Diet and exercise
- Stable dose of metformin
- Sodium-glucose cotransporter-2 (SGLT2) inhibitor
- Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening
- Have a BMI of 27 or greater at screening
Who cannot join
- Have any form of diabetes other than type 2 diabetes
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
Show all 20Show fewer
- hospitalization due to congestive heart failure
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
- basal or squamous cell skin cancer
- in situ carcinomas of the cervix, or
- in situ prostate cancer
- Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
- amylin RA
- dual amylin and calcitonin RA
- glucagon-like peptide-1 receptor (GLP-1) RA
- glucose-dependent insulinotropic peptide (GIP)/GLP-1 RA
- GLP-1/glucagon (GCG) RAs, or
- GIP/GLP-1/GCG RAs
- Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides
- Have used insulin for diabetic control within the prior year (short term use in certain situations allowed
Trial locations and contacts
42 sites in 4 countries.
42 sites in 4 countries
United States26 sites
SKY Clinical Research Network Group-Brown
Atlanta, Georgia, 30331
Northwest Clinical Research Center
Bellevue, Washington, 98007
Mercy Family Clinic
Dallas, Texas, 75208
Velocity Clinical Research, Dallas
Dallas, Texas, 75230
PriMED Clinical Research
Dayton, Ohio, 45429
Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
Gilbert, Arizona, 85296
Biopharma Informatic, LLC
Houston, Texas, 77043
PlanIt Research, PLLC
Houston, Texas, 77079
Research Physicians Network, LLC
Houston, Texas, 77089
Vector Clinical Trials
Las Vegas, Nevada, 89128
Teak Research Consults
Lawrenceville, Georgia, 30043
Eastern Virginia Medical School (EVMS) Medical Group
Norfolk, Virginia, 23510
Synexus Clinical Research US, Inc.
Phoenix, Arizona, 85020
Rainier Clinical Research Center
Renton, Washington, 98057
Aavon Clinical Trials
Richmond, Texas, 77407
Clinical Research Partners, LLC
Richmond, Virginia, 23226
AGILE Clinical Research Trials, LLC
Sandy Springs, Georgia, 30328
Consano Clinical Research, LLC
Shavano Park, Texas, 78231
Pivotal Research Solutions
Stonecrest, Georgia, 30038
Precision Clinical Research
Sunrise, Florida, 33351
Universal Research Group
Tacoma, Washington, 98405
Premier Research
Trenton, New Jersey, 08611
Pima Heart
Tucson, Arizona, 85741
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, 30291
Texas Valley Clinical Research
Weslaco, Texas, 78596
Kalo Clinical Research
West Valley City, Utah, 84120
Australia8 sites
Emeritus Research
Botany, 2019
Core Research Group
Brisbane, 4064
Emeritus Research
Camberwell, 3124
Cornerstone Dermatology
Coorparoo, 4151
Momentum Darlinghurst
Darlinghurst, Sydney, 2010
CDH Research Institute Pty Ltd
Maroochydore, 4558
Momentum Sunshine
Melbourne, 3021
AIM Research
Merewether, 2291
Argentina6 sites
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, C1056ABI
CENUDIAB
Buenos Aires, C1440AAD
CEDIC
CABA, C1060ABN
Instituto de Investigaciones Clínicas Córdoba
Córdoba, 5000
Clínica Universitaria Reina Fabiola
Córdoba, X50004FHP
Go Centro Medico San Nicolás
San Nicolás, 2900
Puerto Rico2 sites
San Juan Bautista School of Medicine - Clinical Research Unit
Caguas, 00726
Mgcendo Llc
San Juan, 00921
About this study
Official title: A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Being tested
- Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo
- Keywords
- GIP, Amylin
- Medical subject headings
- Obesity, Overweight, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MacupatideDrug
Also called LY3532226
Administered SC
EloralintideDrug
Also called LY3841136
Administered SC
Macupatide PlaceboDrug
Administered SC
Eloralintide PlaceboDrug
Administered SC
| Study group | Role | What they receive |
|---|---|---|
| Macupatide (Macupatide + Eloralintide Placebo) | Experimental | Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC Receives: Drug: Macupatide; Drug: Eloralintide Placebo |
| Eloralintide (Elorlintide + Macupatide Placebo) | Experimental | Participants will be administered eloralintide SC and macupatide placebo SC Receives: Drug: Eloralintide; Drug: Macupatide Placebo |
| Macupatide + Eloralintide | Experimental | Participants will be administered eloralintide SC and macupatide SC Receives: Drug: Macupatide; Drug: Eloralintide |
| Placebo (Macupatide Placebo + Elorlintide Placebo) | Placebo comparator | Participants will be administered eloralintide placebo SC and macupatide placebo SC Receives: Drug: Macupatide Placebo; Drug: Eloralintide Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 32
Secondary outcomes (3)
Change from Baseline in Hemoglobin A1c (HbA1c)
Measured: Baseline, Week 32
Change from Baseline in Body Mass Index (BMI)
Measured: Baseline, Week 32
Change from Baseline in Fasting Glucose
Measured: Baseline, Week 32
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Oct 2025
- Study start16 Oct 2025
- Primary completionMar 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07215559
- Sponsor's protocol ID
- 27721
- Other IDs
- J2V-MC-GZLF
- Status last verified
- Oct 2026
- First submitted
- 9 Oct 2025
- Last updated
- 9 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
- ClinicalTrials.gov ID
- NCT07215559
- Acronym / sponsor ID
- 27721
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Keywords
- GIP, Amylin
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 16 Oct 2025 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 10 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Macupatide (Macupatide + Eloralintide Placebo) | Experimental | Drug: Macupatide, Drug: Eloralintide PlaceboParticipants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC |
| Eloralintide (Elorlintide + Macupatide Placebo) | Experimental | Drug: Eloralintide, Drug: Macupatide PlaceboParticipants will be administered eloralintide SC and macupatide placebo SC |
| Macupatide + Eloralintide | Experimental | Drug: Macupatide, Drug: EloralintideParticipants will be administered eloralintide SC and macupatide SC |
| Placebo (Macupatide Placebo + Elorlintide Placebo) | Placebo comparator | Drug: Macupatide Placebo, Drug: Eloralintide PlaceboParticipants will be administered eloralintide placebo SC and macupatide placebo SC |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Have type 2 diabetes
- Have an HbA1c ≥7.5% to ≤10.5% at screening
- Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
- Have had a stable body weight (<5% body weight gain and/or loss) for the 3 months prior to screening
- Have a BMI of 27 or greater at screening
Key exclusion criteria (20 listed)
- Have any form of diabetes other than type 2 diabetes
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
- Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MacupatideAlso: LY3532226Administered SC | Drug | Macupatide (Macupatide + Eloralintide Placebo), Macupatide + Eloralintide |
| EloralintideAlso: LY3841136Administered SC | Drug | Eloralintide (Elorlintide + Macupatide Placebo), Macupatide + Eloralintide |
| Macupatide PlaceboAdministered SC | Drug | Eloralintide (Elorlintide + Macupatide Placebo), Placebo (Macupatide Placebo + Elorlintide Placebo) |
| Eloralintide PlaceboAdministered SC | Drug | Macupatide (Macupatide + Eloralintide Placebo), Placebo (Macupatide Placebo + Elorlintide Placebo) |
Primary outcome
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 32
3 secondary outcomes
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 32
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 32
Change from Baseline in Fasting Glucose
Time frame: Baseline, Week 32
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Obesity
RecruitingPhase 4
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Class I/II Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Overweight and Obesity
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
42 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Macupatide and Eloralintide in people with Obesity and Overweight, run by Eli Lilly and Company at 42 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 42 sites in United States, Australia, Argentina, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change from Baseline in Body Weight (time frame: Baseline, Week 32). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.